Human Cell Line-derived Recombinant Factor VIII (Human-cl-rhFVIII) in Previously Untreated Patients
NCT01712438 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 110
Last updated 2021-01-19
Summary
Investigate the inhibitor development rate of Human cl rhFVIII in previously untreated patients with severe Hemophilia A.
Conditions
- Severe Hemophilia A
Interventions
- BIOLOGICAL
-
Human cl rhFVIII
Sponsors & Collaborators
-
Octapharma
lead INDUSTRY
Principal Investigators
-
Sigurd Knaub · Octapharma
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Sex
- MALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2013-02-28
- Primary Completion
- 2018-12-14
- Completion
- 2019-12-20
Countries
- United States
- Belarus
- Canada
- France
- Georgia
- Germany
- India
- Italy
- Moldova
- Morocco
- Poland
- Portugal
- Russia
- Slovenia
- Spain
- Ukraine
- United Kingdom
Study Locations
More Related Trials
-
Assess the Efficacy and Safety of Personalized Prophylaxis Human-cl rhFVIII in Patients With Severe Haemophilia A
NCT02256917 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A Patients
NCT00157157 ·Status: COMPLETED ·Phase: PHASE3
-
An Open-label Safety, Efficacy and Pharmacokinetic Study of a Recombinant FVIII Compared to Recombinant Human Antihemophilic FVIII in Patients With Severe Hemophilia A
NCT01486927 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Study of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Subjects With Severe Hemophilia A
NCT01027377 ·Status: COMPLETED ·Phase: PHASE1
-
An Open Label Study to Determine the Safety and Efficacy of Replacement Factor VIII Protein (Known as rFVIIIFc) in Previously Untreated Males With Severe Hemophilia A
NCT02234323 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluate Efficacy and Safety of Recombinant Factor VIII （rFVIII）Treatment of Severe or Moderately Severe Hemophilia A
NCT02930317 ·Status: UNKNOWN ·Phase: PHASE3
-
Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Acquired Hemophilia A
NCT01178294 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Congenital Hemophilia A
NCT01434511 ·Status: TERMINATED ·Phase: PHASE3
-
A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B
NCT02053792 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy Study of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients Undergoing Surgery
NCT00157105 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Efficacy and Safety Study of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Pediatric Patients in Canada With Hemophilia A - A Continuation of Baxter Study 060101
NCT00189982 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Participants With Hemophilia A Previously Treated With FVIII Products
NCT06738485 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Safety and Efficacy Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B
NCT01496274 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Cooperative Study of Factor VIII Inhibitors
NCT00000582 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery
NCT01561391 ·Status: COMPLETED ·Phase: PHASE4
-
Study of Pharmacokinetics, Efficacy and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients - A Continuation of Clinical Study 069901
NCT00157053 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
An Open Label Study to Determine the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A.
NCT04456387 ·Status: COMPLETED ·Phase: PHASE3
-
Study Evaluating Inhibitor Specificity in Hemophilia A
NCT00151385 ·Status: WITHDRAWN ·Phase: PHASE4
-
An Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia A
NCT02172950 ·Status: COMPLETED ·Phase: PHASE3
-
Prophylaxis Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia A
NCT00243386 ·Status: COMPLETED ·Phase: PHASE4
-
A Clinical Study of Recombinant Human Coagulation Factor VIII for Injection in Patients With Severe Hemophilia A
NCT06297655 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Study Evaluating ReFacto AF in Severe Hemophilia A
NCT00037544 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Pharmacokinetics of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection
NCT03747653 ·Status: UNKNOWN
-
Safety and Pharmacokinetic Study of a Recombinant Coagulation Factor IX Albumin Fusion Protein in Subjects With Hemophilia B
NCT01233440 ·Status: COMPLETED ·Phase: PHASE1
-
Long-Term Safety and Efficacy of rFIXFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia B
NCT01425723 ·Status: COMPLETED ·Phase: PHASE3